Alzheimer's disease: SPECT and PET tracers for beta-amyloid imaging

Current Alzheimer Research

Volumn 7, Issue 6, 2010, Pages 477-486

  Valotassiou, V ^a   Archimandritis, S ^b   Sifakis, N ^c   Papatriantafyllou, J ^d   Georgoulias, P ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Alzheimer's Disease; Beta Amyloid; PET; SPECT

Indexed keywords

AMYLOID BETA PROTEIN; CONGO RED; FLUORODEOXYGLUCOSE F 18; MATRIX METALLOPROTEINASE; RADIOLIGAND; THIOFLAVINE; TRACER;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BRAIN BLOOD FLOW; BRAIN MAPPING; BRAIN PERFUSION; DRUG PENETRATION; DRUG UPTAKE; GLUCOSE METABOLISM; HISTOLOGY; HUMAN; NEUROFIBRILLARY TANGLE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BENZOTHIAZOLES; BRAIN MAPPING; CEREBRAL CORTEX; CONGO RED; FLUORODEOXYGLUCOSE F18; HUMANS; NEUROFIBRILLARY TANGLES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; THIAZOLES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 78549279458     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510792231757     Document Type: Article

References (85)

1. Vickers JC, Dickson TC, Adlard PA, Saunders HL, King CE, McCormack G. The cause of neuronal degeneration in Alzheimer's disease. Prog Neurobiol 60: 139-165 (2000).
2. De Strooper B, König G. Alzheimer's disease. A firm base for drug development. Nature 402: 471-472 (1999).
3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl.) 82: 239-259 (1991).
4. Braak E, Griffing K, Arai K, Bohl J, Bratzke H, Braak H. Neuropathology of Alzheimer's disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci 249: 14-22 (1999).
5. Wu C, Pike VW, Wang Y. Amyloid Imaging: From Benchtop to Bedside. Curr Top Dev Biol 70: 171-213 (2005).
6. Price JL. Diagnostic criteria for Alzheimer's disease. Neurobiol Aging 18: 67-70 (1997).
7. Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, et al. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 18: 2161-2173 (1998).
8. Knopman DS, DeKosky ST, Cummings JL Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidencebased review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1143-1153 (2001).
9. Gee AD. Neuropharmacology and drug development. Br Med Bull 65: 169-177 (2003).
10. Valotassiou V, Wozniak G, Sifakis N, Demakopoulos N, Georgoulias P. Radiopharmaceuticals in neurological and psychiatric disorders. Curr Clin Pharmacol 3: 99-107 (2008).
11. Ichimyia A. Functional and structural brain imagings in dementia. Psychiatry Clin Neurosci 52: 223-225 (1998).
12. Pakrasi S, O'Brien JT. Emission tomography in dementia. Nucl Med Commun 26: 189-196 (2005).
13. Dickson DW. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging 18: 21-26 (1997).
14. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 3: 519-527 (2004).
15. Walker LC, Price DL, Voytko ML, Schenk DB. Labeling of cerebral amyloid in vivo with a monoclonal antibody. J Neuropathol Exp Neurol 53: 377-383 (1994).
16. Marshall JR, Stimson ER, Ghilardi JR, Vinters HV, Mantyh PW, Maggio JE. Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. Bioconjug Chem 13: 276-284 (2002).
17. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12: 295-298 (2002).
18. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, et al. The binding of 2-(4'-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23: 2086-2092 (2003).
19. Shimadzu H, Suemoto T, Suzuki M, Shiomitsu T, Okamura N, Kudo Y, et al. A novel probe for imaging amyloid: Synthesis of F-18 labelled BF-108, an acridine orange analog. J Labelled Comp Radiopharm 46: 765-772 (2003).
20. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10: 24-35 (2002).
21. Shi J, Perry G, Berridge MS, Aliev G, Siedlak SL, Smith MA, et al. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med 43: 1044-1051 (2002).
22. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. Invivo imaging of Alzheimer disease-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12: 584-595 (2004).
23. 99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease. Eur J Nucl Med 26: 1392-1399 (1999).
24. Klunk WE, Wang Y, Huang G, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 69: 1471-1484 (2001).
25. Ashburn TT, Han H, McGuinness BF, Lansbury PT Jr. Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides. Chem Biol 3: 351-358 (1996).
26. Klunk WE, Pettegrew JW, Abraham DJ. Quantitative evaluation of Congo red binding to amyloidlike proteins with a -pleated sheet conformation. J Histochem Cytochem 37: 1273-1281 (1989).
27. Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the -amyloid protein of Alzheimer's disease. Neurobiol Aging 15: 691-698 (1994).
28. Zhen W, Han H, Anguiano M, Lemere CA, Cho CG, Lansbury PT Jr. Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain. J Med Chem 42: 2805-2815 (1999).
29. Tubis M, Blahd W, Nordyke R. The preparation and use of radioiodinated Congo red in detecting amyloidosis. J Am Pharm Assoc 49: 422-425 (1960).
30. Kung HF, Kung MP, Zhuang ZP, Hou C, Lee CW. Iodinated tracers for imaging amyloid plaques in the brain. Mol Imaging Biol 5: 418-426 (2003).
31. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 61: 797-805 (2002).
32. Zhuang ZP, Kung MP, Hou C, Skovronsky DM, Gur TL, Plössl K, et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 44: 1905-1914 (2001).
33. Zhuang ZP, Kung MP, Hou C, Plössl K, Skovronsky D, Gur TL, et al. IBOX(2-(4'-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. Nucl Med Biol 28: 887-894 (2001).
34. Ono M, Kung MP, Hou C, Kung HF. Benzofuran derivatives as Abeta-aggregate-specific imaging agents for Alzheimer's disease. Nucl Med Biol 29: 633-642 (2002).
35. Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, et al. IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res 956: 202-210 (2002).
36. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46: 2740-2754 (2003).
37. Wang Y, Klunk WE, Huang GF, Debnath ML, Holt DP, Mathis CA. Synthesis and evaluation of 2-(3'-iodo-4'-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. J Mol Neurosci 19: 11-16 (2002).
38. Bateman RJ, Eidelberg D. Testing a test for Alzheimer disease. Neurology 68: 482-483 (2007).
39. Lockhart A, Judd L, Ye DB, Merritt AT, Lowe PN, Morgenstern JL, et al. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem 280: 7677-7684 (2005).
40. Ye L, Morgenstern JL, Gee AD, Hong G, Brown J, Lockhart A. Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem 280: 23599-23604 (2005).
41. Nordberg A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur J Nucl Med Mol Imaging 35 (Suppl 1): 46-50 (2008).
42. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791-1800 (2002).
43. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1: 103-116 (1991).
44. Price JL, Morris JC. Tangles and plaques in nondemented aging and preclinical Alzheimer's disease. Ann Neurol 45: 358-368 (1999).
45. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 17: 101-118 (2001).
46. Klunk WE, Mathis CA. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol 21: 683-687 (2008).
47. 18F-Flutemetamol in healthy volunteers and patients with probable Alzheimer Disease. J Nucl Med 50: 1251-1259 (2009).
48. Jacobson A, Petric A, Hogenkamp D, Sinur A, Barrio JR. 1, 1-Dicyano-2-(6-dimethylaminonaphthalen-2-yl)propene (DDNP): a solvent polarity and viscosity sensitive fluorophore for fluorescence microscopy. J Am Chem Soc 118: 5572-5579 (1996).
49. Agdeppa ED, Kepe V, Petri A, Satyamurthy N, Liu J, Huang SC, et al. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F] fluoroethyl) (methyl) amino]-2-naphthyl] ethylidene) malononitrile. Neuroscience 117: 723-730 (2003).
50. Agdeppa ED, Kepe V, Liu J, Small GW, Huang S, Petric A, et al. 2-Dialkylamino-6 Acylmalononitrile Substituted Naphthalenes (DDNP Analogs): Novel Diagnostic and Therapeutic Tools in Alzheimer's Disease. Mol Imaging Biol 5: 404-417 (2003).
51. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 21: 189 (2001).
52. Barrio JR, Huang SC, Cole G, Satyamurthy N, Petric A, Phelps ME, et al. PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe. J Labelled Compd Radiopharm 42: 194-195 (1999).
53. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355: 2652-2663 (2006).
54. 18F-AV-45: a PET agent for A plaques in the brain. J Nucl Med 50: 1887-1894 (2009).
55. Glenner G, Wong C. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 3: 885-890 (1984).
56. Pardridge WM, Vinters HV, Yang J, Eisenberg J, Choi T, Tourtellote WW, et al. Amyloid angiopathy of Alzheimer's disease: amino acid composition and partial sequence of a 4200 dalton peptide isolated from cortical microvessels. J Neurochem 49: 1394-1401 (1987).
57. Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci USA 91: 5705-5709 (1994).
58. Vorbrodt AW, Dobrogowska DH, Tarnawski M, Meeker HC, Carp RI. Immunocytochemical evaluation of blood-brain barrier to endogenous albumin in scrapie-infected mice. Acta Neuropathol 93: 341-348 (1997).
59. Yamaguchi H, Yamazaki T, Lemere CA, Frosch MP, Selkoe DJ. Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol 141: 249-259 (1992).
60. Wu D, Yang J, Pardridge WM. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest 100: 1804-1812 (1997).
61. Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA. Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease. Mol Neurobiol 9: 107-113 (1994).
62. Majocha RE, Reno JM, Friedland RP, Van Haight C, Lyle LR, Marotta CA. Development of a monoclonal antibody specific for beta/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy. J Nucl Med 33: 2184-2189 (1992).
63. Friedland RP, Kalaria R, Berridge M, Miraldi F, Hedera P, Reno J, et al. Neuroimaging of vessel amyloid in Alzheimer's disease. Ann N Y Acad Sci 826: 242-247 (1997).
64. Bickel U, Lee VM, Trojanowski JQ, Pardridge WM. Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: A potential probe for Alzheimer's disease. Bioconjug Chem 5: 119-125 (1994).
65. Friedland RP, Shi J, Lamanna JC, Smith MA, Perry G. Prospects for noninvasive imaging of brain amyloid beta in Alzheimer's disease. Ann N Y Acad Sci 903: 123-128 (2000).
66. Walker LC, Price DL, Voytko ML, Schenk DB. Labeling of cerebral amyloid in vivo with a monoclonal antibody. J Neuropathol Exp Neurol 53: 377-383 (1994).
67. Lovat LB, O'Brien AA, Armstrong SF, Madhoo S, Bulpitt CJ, Rossor MN et al. Scintigraphy with 123I-serum amyloid P component in Alzheimer disease. Alzheimer Dis Assoc Disord 12: 208-210 (1998).
68. Maggio JE, Stimson ER, Ghilard JR, Allen CJ, Dahl CE, Whitcomb DC, et al. Reversible in vitro growth of Alzheimer disease - amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci 89: 5462-5466 (1992).
69. 1-40 labels amyloid deposits in the aged primate brain in vivo. NeuroReport 7: 2607-2611 (1996).
70. 1-40/vector complex. Proc Natl Acad Sci USA 92: 10227-10231 (1995).
71. 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjug Chem 10: 502-511 (1999).
72. Wengenack TM, Curran GL, Poduslo JF. Targeting Alzheimer amyloid plaques in vivo. Nat Biotechnol 18: 868-872 (2000).
73. 111In Chelation, Conjugation to Poly(ethylene glycol) Biotin Linkers, and Autoradiography with Alzheimer's Disease Brain Sections. Bioconjug Chem 11: 380-386 (2000).
74. Kurihara A, Pardridge WM. Imaging brain tumors by targeting peptide radiopharmaceuticals throught the blood brain barrier. Cancer Res 54: 6159-6163 (1999).
75. Hartung D, Schäfers M, Fujimoto S, Levkau B, Narula N, Kopka K, et al. Targeting of matrix metalloproteinase activation for non-invasive detection of vulnerable atherosclerotic lesions. Eur J Nucl Med Mol Imaging 34: 1-8 (2007).
76. Damjanovski S, Amano T, Li Q, Ueda S, Shi YB, Ishizuya-Oka A. Role of ECM remodeling in thyroid hormone-dependent apoptosis during anuran metamorphosis. Ann NY Acad Sci 926: 180-191 (2000).
77. Warner RL, Lewis CS, Beltran L, Younkin EM, Varani J, Johnson KJ. The role of metalloelastase in immune complex-induced acute lung injury. Am J Pathol 158: 2139-2144 (2001).
78. Leake A, Morris CM, Whateley J. Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neurosci Lett 291: 201-203 (2000).
79. Calliste CA, Le Bail JC, Trouillas P, Pouget C, Habrioux G, Chulia AJ, et al. Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities. Anticancer Res 21: 3949-3956 (2001).
80. Rezai-Zadeh K, Ehrhart J, Bai Y, Sanberg PR, Bickford P, Tan J, et al. Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. J Neuroinflammation 5: 41 (2008).
81. Ono M, Yoshida N, Ishibashi K, Haratake M, Arano Y, Mori H, et al. Radioiodinated Flavones for in Vivo Imaging of -Amyloid Plaques in the Brain. J Med Chem 48: 7253-7260 (2005).
82. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 87: 172-181 (2003).
83. Ryu E, Choe Y, Lee K, Choi Y, Kim B. Circumin and dehydrozingerone derivatives: synthesis, radiolabeling and evaluation for bete-amyloid plaque imaging. J Med Chem 49: 6111-6119 (2006).
84. Ono M, Haratake M, Mori H, Nakayama M. Novel chalcones as probes for in vivo imaging of b-amyloid plaques in Alzheimer's brains. Bioorg Med Chem 15: 6802-6809 (2007).
85. Ono M, Maya Y, Haratake M, Ito K, Mori H, Nakayama M. Aurones serve as probes of b-amyloid plaques in Alzheimer's disease. Biochem Biophys Res Commun 361: 116-121 (2007).